Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PEPG

PepGen Inc

Dec 01 • 04:00PM ET

5.37

Dollar change +0.47
Percentage change 9.59	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.12	Insider Own	23.02%	Shs Outstand	23.71M	Perf Week	19.87%
Market Cap	127.86M	Forward P/E	-	EPS next Y	-3.66	Insider Trans	-0.57%	Shs Float	18.33M	Perf Month	5.29%
Income	-74.07M	PEG	-	EPS next Q	-1.01	Inst Own	72.35%	Short Float / Ratio	1.27% / 3.76	Perf Quarter	-16.87%
Sales	0.00M	P/S	-	EPS this Y	20.77%	Inst Trans	-0.64%	Short Interest	0.23M	Perf Half Y	-66.73%
Book/sh	5.29	P/B	1.02	EPS next Y	-4.57%	ROA	-39.74%	Target Price	22.80	Perf Year	-64.10%
Cash/sh	5.44	P/C	0.99	EPS next 5Y	-	ROE	-46.47%	52W Range	3.72 - 20.00	Perf YTD	-59.84%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-51.68%	52W High	-73.15%	Beta	0.95
Dividend %	-	Quick Ratio	6.35	Sales past 5Y	0.00%	Gross Margin	-	52W Low	44.35%	ATR	0.45
Employees	45	Current Ratio	6.35	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	61.96	Volatility	9.35% 9.97%
Optionable	No	Debt/Eq	0.16	EPS Q/Q	-23.97%	Profit Margin	-	Rel Volume	0.58	Prev Close	4.90
Shortable	Yes	LT Debt/Eq	0.14	Earnings	Nov 08 BMO	Payout	-	Avg Volume	62.15K	Price	5.37
Recom	1.00	SMA20	17.97%	SMA50	8.40%	SMA200	-43.93%	Volume	35,930	Change	9.59%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-21-22	Initiated	H.C. Wainwright	Buy	$26

Nov-15-23 08:00AM	PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors (GlobeNewswire)
Nov-08-23 08:00AM	PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire) -10.40%
Oct-12-23 07:00AM	PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +7.22%
Sep-27-23 04:16PM	PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology (GlobeNewswire)
Sep-06-23 04:05PM	PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1 (GlobeNewswire)
08:00AM	Loading…
08:00AM	PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Companys Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences (GlobeNewswire)
Sep-01-23 08:00AM	PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-08-23 08:15AM	PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Jun-13-23 04:05PM	PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1 (GlobeNewswire) +10.87%
May-31-23 11:44AM	PepGen (PEPG) Down on Clinical Hold for DM1 Candidate (Zacks) -5.07%
May-30-23 04:05PM	PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
May-18-23 07:00AM	PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
May-11-23 07:00AM	PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
May-04-23 08:00AM	PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference (GlobeNewswire)
Apr-17-23 08:00AM	PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting (GlobeNewswire) +23.09%
04:05PM	Loading…
Apr-13-23 04:05PM	PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +6.07%
Mar-27-23 02:25AM	PepGen Inc. (NASDAQ:PEPG) Q4 2022 Earnings Call Transcript (Insider Monkey) -16.15%
Mar-23-23 04:05PM	PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments (GlobeNewswire)
Mar-22-23 08:00AM	PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference (GlobeNewswire)
Mar-21-23 04:05PM	PepGen to Participate in the Stifel 2023 CNS Days Conference (GlobeNewswire)
Mar-16-23 08:00AM	PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call (GlobeNewswire) +6.99%
Mar-13-23 08:00AM	PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference (GlobeNewswire)
Feb-27-23 08:50AM	PepGen, Inc. (PEPG) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -6.02%
Feb-09-23 08:00AM	PepGen to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire) -5.07%
Jan-31-23 08:50AM	Here's Why Momentum in PepGen, Inc. (PEPG) Should Keep going (Zacks)
Jan-16-23 05:10AM	Companies Like PepGen (NASDAQ:PEPG) Are In A Position To Invest In Growth (Simply Wall St.)
Jan-13-23 08:50AM	Here's What Could Help PepGen, Inc. (PEPG) Maintain Its Recent Price Strength (Zacks)
Dec-21-22 02:25PM	Why This PepGen Analyst Is Bullish On The Biotech Stock (Benzinga)
Dec-07-22 08:00AM	PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies (GlobeNewswire)
Dec-01-22 09:55AM	Wall Street Analysts See a 50% Upside in PepGen, Inc. (PEPG): Can the Stock Really Move This High? (Zacks) -6.42%
08:50AM	Loading…
Nov-21-22 08:50AM	What Makes PepGen, Inc. (PEPG) a Good Fit for 'Trend Investing' (Zacks) +5.54%
Nov-15-22 09:55AM	Wall Street Analysts Predict a 68% Upside in PepGen, Inc. (PEPG): Here's What You Should Know (Zacks)
Nov-14-22 08:00AM	PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates (GlobeNewswire) +8.33%
Nov-10-22 08:00AM	PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) +12.92%
Nov-08-22 08:00AM	PepGen to Participate in the Stifel 2022 Healthcare Conference (GlobeNewswire)
Oct-13-22 01:00PM	PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress (GlobeNewswire)
Sep-28-22 01:59PM	PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst (Benzinga) +110.19%
09:25AM	PepGen Touts Encouraging Early-Stage Data From Duchenne Program (Benzinga)
06:00AM	PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-22-22 08:00AM	PepGen Appoints Habib Dable to Board of Directors (GlobeNewswire)
Sep-04-22 07:17AM	3 IPO Stocks to Watch in September (TipRanks)
Aug-12-22 08:00AM	PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) -6.70%
Aug-08-22 10:51AM	We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth (Simply Wall St.)
Jul-22-22 07:45AM	PepGen Appoints Caroline Godfrey, Ph.D. to the Companys Scientific Advisory Board (GlobeNewswire)
Jun-16-22 08:30AM	PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) +12.70%
May-27-22 05:22PM	Covetrus and PepGen Stock See Action From Activist Investors (Barrons.com) +5.63%
May-05-22 11:34PM	PepGen Announces Pricing of Initial Public Offering (GlobeNewswire)

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McArthur James G	President and CEO	Jun 08	Option Exercise	2.71	2,381	6,453	2,381	Jun 09 07:06 PM
McArthur James G	President and CEO	Jun 08	Sale	16.04	2,381	38,188	0	Jun 09 07:06 PM
McArthur James G	President and CEO	Jun 07	Option Exercise	2.71	8,419	22,815	8,419	Jun 08 05:23 PM
McArthur James G	President and CEO	Jun 07	Sale	16.23	8,419	136,618	0	Jun 08 05:23 PM
McArthur James G	President and CEO	Jun 06	Option Exercise	2.71	18,150	49,186	18,150	Jun 08 05:23 PM
McArthur James G	President and CEO	Jun 06	Sale	16.18	18,150	293,660	0	Jun 08 05:23 PM
McArthur James G	President and CEO	Jun 05	Option Exercise	2.71	500	1,355	500	Jun 06 04:19 PM
McArthur James G	President and CEO	Jun 05	Sale	16.06	500	8,028	0	Jun 06 04:19 PM
McArthur James G	President and CEO	Jun 02	Option Exercise	2.71	1,800	4,878	1,800	Jun 06 04:19 PM
McArthur James G	President and CEO	Jun 02	Sale	16.04	1,800	28,863	0	Jun 06 04:19 PM
Goyal Jaya	EVP, Res. & Preclin. Dev.	Mar 24	Option Exercise	10.88	392	4,265	392	Mar 28 07:36 PM
Goyal Jaya	EVP, Res. & Preclin. Dev.	Mar 24	Sale	20.00	392	7,840	0	Mar 28 07:36 PM
Goyal Jaya	EVP, Res. & Preclin. Dev.	Feb 08	Option Exercise	10.88	644	7,007	644	Feb 08 05:42 PM
Goyal Jaya	EVP, Res. & Preclin. Dev.	Feb 08	Sale	17.00	644	10,948	0	Feb 08 05:42 PM
Goyal Jaya	EVP, Res. & Preclin. Dev.	Feb 07	Option Exercise	10.88	3,679	40,028	3,679	Feb 08 05:42 PM
Goyal Jaya	EVP, Res. & Preclin. Dev.	Feb 07	Sale	17.18	3,679	63,213	0	Feb 08 05:42 PM
Goyal Jaya	EVP, Res. & Preclin. Dev.	Feb 06	Option Exercise	10.88	1,677	18,246	1,677	Feb 08 05:42 PM
Goyal Jaya	EVP, Res. & Preclin. Dev.	Feb 06	Sale	17.04	1,677	28,568	0	Feb 08 05:42 PM
Svenstrup Niels	SVP, Chem. Mfg & Controls	Dec 19	Option Exercise	2.71	10,000	27,100	10,000	Dec 19 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PEPG

PepGen Inc

Upgrade your FINVIZ experience